JP2024526279A - セマグルチドデポー系及びその使用 - Google Patents

セマグルチドデポー系及びその使用 Download PDF

Info

Publication number
JP2024526279A
JP2024526279A JP2023581040A JP2023581040A JP2024526279A JP 2024526279 A JP2024526279 A JP 2024526279A JP 2023581040 A JP2023581040 A JP 2023581040A JP 2023581040 A JP2023581040 A JP 2023581040A JP 2024526279 A JP2024526279 A JP 2024526279A
Authority
JP
Japan
Prior art keywords
semaglutide
pharmaceutical composition
long
parenteral pharmaceutical
acting parenteral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023581040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526279A5 (https=
Inventor
ザッツ，ガリナ
キメルマン，ナダブ ブライヒ
ラブノフ，シャイ
マロム，エフド
Original Assignee
マピ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マピ ファーマ リミテッド filed Critical マピ ファーマ リミテッド
Publication of JP2024526279A publication Critical patent/JP2024526279A/ja
Publication of JP2024526279A5 publication Critical patent/JP2024526279A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023581040A 2021-07-05 2022-07-04 セマグルチドデポー系及びその使用 Pending JP2024526279A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163218405P 2021-07-05 2021-07-05
US63/218,405 2021-07-05
US17/534,533 2021-11-24
US17/534,533 US11865213B2 (en) 2021-07-05 2021-11-24 Semaglutide depot systems and use thereof
PCT/IL2022/050708 WO2023281495A1 (en) 2021-07-05 2022-07-04 Semaglutide depot systems and use thereof

Publications (2)

Publication Number Publication Date
JP2024526279A true JP2024526279A (ja) 2024-07-17
JP2024526279A5 JP2024526279A5 (https=) 2025-07-10

Family

ID=84801375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023581040A Pending JP2024526279A (ja) 2021-07-05 2022-07-04 セマグルチドデポー系及びその使用

Country Status (8)

Country Link
US (2) US11865213B2 (https=)
EP (1) EP4366759A4 (https=)
JP (1) JP2024526279A (https=)
AU (1) AU2022308705A1 (https=)
CA (1) CA3220567A1 (https=)
IL (1) IL309789A (https=)
MX (1) MX2024000050A (https=)
WO (1) WO2023281495A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
NL2036269B1 (en) 2023-11-14 2025-05-23 Nanomi B V Peptide microparticle compositions and related methods
KR102930984B1 (ko) * 2024-01-29 2026-02-25 주식회사 티온랩테라퓨틱스 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2025229403A1 (en) * 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
CN121015560B (zh) * 2025-10-30 2026-01-30 上海银诺医药技术有限公司 依苏帕格鲁肽α纳米冻干胶束及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021531A2 (en) * 2006-08-17 2008-02-21 University Of Massachusetts Stabilized emulsions, methods of preparation, and related reduced fat foods
TWI362947B (en) * 2007-03-08 2012-05-01 Univ Kaohsiung Medical Controlled release pharmaceutical composition and manufacture method thereof
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
EP2866825B1 (en) * 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
BR112016022550B1 (pt) * 2014-03-31 2023-03-28 Pharmathen S.A Processo para a preparação de microesferas de plga de acetato de octreotida
CN105963257B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CA3040906A1 (en) * 2016-10-20 2018-04-26 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
US20190380967A1 (en) 2017-01-23 2019-12-19 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
KR102047983B1 (ko) 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
CN110101846B (zh) 2018-02-01 2022-09-23 齐鲁制药有限公司 一种低突释率的索玛鲁肽微球及其制备方法
US20210162013A1 (en) 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
US20220183964A1 (en) 2019-04-11 2022-06-16 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled, sustained release of therapeutic agents
JP7336813B2 (ja) 2019-07-29 2023-09-01 ペプトロン インコーポレイテッド レボドパ誘発性ジスキネジアの治療または進行抑制用の薬学組成物
CN113018277B (zh) * 2019-12-25 2023-10-31 丽珠医药集团股份有限公司 注射用缓释制剂及其制备方法
CN115484935A (zh) 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
WO2022003662A1 (en) * 2020-06-29 2022-01-06 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
AU2023234747A1 (en) * 2022-03-17 2024-09-12 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Also Published As

Publication number Publication date
IL309789A (en) 2024-02-01
CA3220567A1 (en) 2023-01-12
WO2023281495A1 (en) 2023-01-12
MX2024000050A (es) 2024-03-08
US20240148653A1 (en) 2024-05-09
EP4366759A1 (en) 2024-05-15
US20230014750A1 (en) 2023-01-19
US11865213B2 (en) 2024-01-09
EP4366759A4 (en) 2025-04-09
AU2022308705A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
JP2024526279A (ja) セマグルチドデポー系及びその使用
EP2157967B1 (en) Suspension formulations of insulinotropic peptides and uses thereof
US20230256058A1 (en) Low burst-release liraglutide depot systems
AU2018201551B2 (en) Rapid establishment and/or termination of substantial steady-state drug delivery
KR101034888B1 (ko) 지속제어 방출 양상을 갖는 당조절 펩타이드 함유 생분해성고분자 미립구 및 그 제조방법
EP3524261B1 (en) Exendin for use in treating diabetes and reducing body weight
CN104248623B (zh) 使用非水性载体的持续释放制剂
KR20210103985A (ko) Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
AU2005316545A1 (en) Sustained delivery formulations of octreotide compounds
AU2023234747A1 (en) Depot systems comprising cariprazine or salts thereof
KR102442807B1 (ko) 초기 방출 제어된 데포 조성물 및 이의 제조방법
US12514908B2 (en) Semaglutide depot systems and use thereof
HK40104236A (zh) 索玛鲁肽贮库系统及其用途
CN117615778A (zh) 索玛鲁肽贮库系统及其用途
JP2025511372A (ja) 新規組成物
EP4721726A1 (en) Pharmaceutical composition comprising glp-1 receptor agonist, gip/glp-1 receptor agonist and/or glp-1/gip/gcg receptor triple agonist
JPWO2000025803A1 (ja) ベータセルリン蛋白質含有製剤
HK1140417A (en) Suspension formulations of insulinotropic peptides and uses thereof

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250702